Navigation Links
Orchid Gets Approval for Antibiotic Drug from FDA

Chennai:- Pharma major Orchid Chemicals and Pharmaceuticals Ltd has getting approval from US Food and Drug Administration (FDA) for its abbreviated new anti-biotic drug application for Cefepime injection.

Cefepime injection is a life saving cephalosporin antibiotic drug with an annual sale of $190 million, and is used in hospital settings.

"Orchid's Cefepime approval for the US generic market is prestigious, given that it is the first abbreviated new drug application (ANDA) approval received for this product from the FDA. The product has been supplied to Apotex for distribution by them in the US," Orchid's Managing Director K. Raghavendra Rao said here Thursday.

The product is available in three dosage strengths, 500 mg/vial, 1 gram/vial, and 2 grams/vial.

The Chennai-based Orchid has filed 40 ANDAs comprising 29 antibiotic and 11 non-antibiotic products so far with the FDA. It has received approvals for 19 ANDAs, including Cefepime.


'"/>




Page: 1

Related medicine news :

1. Orchid Gets USFDA Nod for Cephalexin
2. Orchid to Buy out Bexel Pharma, US
3. Orchid gets FDA Approval for Cefotaxime Injections
4. Approval for DNA test to detect cystic fibrosis
5. Vaccine For Cervical Cancer Awaits Approval
6. WHO Gives Its Approval For Bird Flu Test Kit
7. FDA Gives Its Approval For Inhaler
8. RotaTeq Gets US Approval
9. Better Communication With FDA Could Speed Up Approval Of New Drugs
10. Nerve Stimulator for Depression Though Not Effective Was Given Approval
11. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Orchid Gets Approval for Antibiotic Drug from FDA

(Date:7/24/2014)... Ariz. July 24, 2014 A new study ... insights into the interplay among bacteria, viruses and the ... HIV-positive men,s infectivity their potential to infect others ... men produce large amounts of virus in their semen ... this "compartmentalization," where different levels of the virus can ...
(Date:7/24/2014)... In signing the Workforce Innovation and ... Atlanta BeltLine Workforce Partnership in Healthcare as one ... ( http://www.whitehouse.gov/ready-to-work ). The Administration called for ... economic strategy and profiled successful local efforts to ... Obama highlights the power of partnerships in Atlanta,” ...
(Date:7/24/2014)... shown that it is possible to predict long-term cancer risk ... that same exposure. The findings, which currently appear in the ... develop simpler and cheaper tests to screen chemicals for their ... decrease in incidence of and mortality from cancer, about 40 ... their lifetime, and around 20 percent will die of it. ...
(Date:7/24/2014)... (Boston)--Minority women who received the Human Papillomavirus Vaccination ... rates of abnormal Pap test results than those ... the journal Sexually Transmitted Diseases . ... Health and School of Medicine conducted a cross-sectional ... undergoing routine cervical cytology testing. HPV status and ...
(Date:7/24/2014)... New York (PRWEB) July 24, 2014 ... lawsuit ( http://www.drugbot.com/testosterone/lawsuit/ ) against the manufacturer of ... the risks associated with the low testosterone injection, ... which was filed in the Ontario Superior Court ... that use of low testosterone therapy is associated ...
Breaking Medicine News(10 mins):Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 3
... ... our nation. HOPSports and Hyper Wear are teaming up to reach Physical Education students ... with Hyper Wear,s safe and effective SandBell® weights. , ... Valencia, CA and Austin, TX (PRWEB) June 29, 2010 -- ...
... ... or Washing Up on Coastal Shores , ... Mission Viejo, California (Vocus) June 28, 2010 -- SafeShot Technologies, LLC , ... by accidental needlesticks and global reuse of contaminated syringes. The recent oil spill in the ...
... oil spill in the Gulf of Mexico, and they are concerned ... to new data from a continuing survey conducted by the University ... consumer confidence poll conducted by The Food Industry Center at the ... respondents said they were aware of the spill and 85 percent ...
... ... by the body and normally known as a neurotransmitter, and is influenced by the amount ... international team led by researchers at UCSF. , ... (Vocus) June 28, 2010 -- The cause of diabetes during pregnancy is ...
... backyard mosquito bites may come down to leaving the vacuuming ... than vacuuming the grass clippings out of catch basins before ... waste in place, the research found. "Catch basins are ... S-methoprene in cleaned catch basins we saw an average of ...
... research project at the University of Leicester is set to ... to invasive autopsies, which many families find to be unpleasant. ... Midlands Forensic Pathology Unit has won a substantive award by ... develop the use of cardiac angiography in relation to near ...
Cached Medicine News:Health News:HOPSports, Inc. Adds SandBell to Award-Winning Training System 2Health News:HOPSports, Inc. Adds SandBell to Award-Winning Training System 3Health News:SafeShot Technologies Calls on Healthcare Industry to Clean Up Environment & Eliminate Death and Suffering Caused by Contaminated Syringes 2Health News:SafeShot Technologies Calls on Healthcare Industry to Clean Up Environment & Eliminate Death and Suffering Caused by Contaminated Syringes 3Health News:SafeShot Technologies Calls on Healthcare Industry to Clean Up Environment & Eliminate Death and Suffering Caused by Contaminated Syringes 4Health News:Gestational Diabetes Linked to Serotonin and Dietary Protein 2Health News:Gestational Diabetes Linked to Serotonin and Dietary Protein 3Health News:Gestational Diabetes Linked to Serotonin and Dietary Protein 4Health News:Gestational Diabetes Linked to Serotonin and Dietary Protein 5Health News:York U study finds better way to battle mosquitoes 2
(Date:7/24/2014)... 2014  Restore Health, a leading personalized medicine ... that it is now offering pharmacogenetics testing that ... based upon their particular genetic makeup. Comprehensive medication ... between a patient,s genetics and their entire drug ... provide this new service to healthcare providers and ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
(Date:7/24/2014)... (NYSE MKT: IG), a New Jersey based specialty generic drug ... second quarter ended June 30, 2014. Second Quarter ... in the second quarter of 2014, an increase of 70% ... of $13.3 million for the six months ended June 30, ... 2013 , Total revenues generated from the sale of ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... QUEBEC CITY, Oct. 2 /PRNewswire-FirstCall/ - AEterna Zentaris ... biopharmaceutical company focused on,endocrine therapy and oncology, today ... patient recruitment for its Phase 2 trial in ... agonist,linked to doxorubicin. The decision to enter the ...
... integrated neurohormonal ... to obesity pharmacotherapy, SAN DIEGO, Oct. 1 Amylin ... for its pipeline obesity,candidates will be presented at the 2008 ... The Obesity Society,s annual,meeting is one of the largest and ...
Cached Medicine Technology:AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: